Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Intrexon T1D Partners

2016 FOUNDED
PRIVATE STATUS
Joint Venture LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Developer of a therapy for the treatment of Type 1 diabetes. The company is focused on development of an antigen-specific immunotherapy both for early-stage patients before they become insulin dependent, and in certain advanced-stage patients for the potential prevention of the requirement for external administration of insulin.

Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 20374 Seneca Meadows Parkway
  • Germantown, MD 20876
  • United States

Intrexon T1D Partners Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Intrexon T1D Partners‘s full profile, request access.

Request full access to PitchBook

Intrexon T1D Partners Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Intrexon T1D Partners‘s full profile, request access.

Request full access to PitchBook